Literature DB >> 2043150

Calcipotriol (MC 903): pharmacokinetics in rats and biological activities of metabolites. A comparative study with 1,25(OH)2D3.

A M Kissmeyer1, L Binderup.   

Abstract

Calcipotriol (MC 903) is a novel analogue of the physiologically active metabolite of vitamin D3, 1 alpha,25-dihydroxycholecalciferol [1,25(OH)2D3]. MC 903 and 1,25(OH)2D3 have similar effects on cell proliferation and cell differentiation in vitro using the human histiocytic lymphoma cell line U 937, but in vivo MC903 has 100-200 times less effect on calcium metabolism. To elucidate this difference, the pharmacokinetic profiles after a single intravenous dose (50 micrograms/kg) of the two compounds to rats were compared. The area under the serum level/time curve (AUC) was more than 100 times higher for 1,25(OH)2D3 than for MC903 and the rate of clearance was more than 100 times higher for MC903 than for 1,25(OH)D3. Serum from MC903 or 1,25(OH)2D3 dosed rats (i.v. 10 micrograms/kg) was investigated for biological activities by incubation of U 937 cells with serum collected 0-24 hr after drug administration. Serum from MC903 dosed rats had an effect only when collected shortly after dosing, whereas serum from 1,25(OH)2D3 dosed rats had an effect when collected up to 4 hr after dosing. The biological effects on the U937 cells of the two major metabolites of MC903 (MC 1046 and MC 1080) were investigated. The metabolites had effects that were more than 100 times weaker than those of the parent compound. The effect of MC903 on proliferative disorders, its fast elimination and the formation of inactive metabolites makes MC903 suitable for topical treatment of psoriasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2043150     DOI: 10.1016/0006-2952(91)90160-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Vitamin D receptor expression in colorectal cancer.

Authors:  M G Thomas; P A Sylvester; P Newcomb; R J Longman
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

2.  PKPD modelling to predict altered disposition of 1α,25-dihydroxyvitamin D3 in mice due to dose-dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation.

Authors:  Holly P Quach; Qi J Yang; Edwin C Chow; Donald E Mager; Stacie Y Hoi; K Sandy Pang
Journal:  Br J Pharmacol       Date:  2015-05-15       Impact factor: 8.739

3.  Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP).

Authors:  A Kissmeyer; I S Mathiasen; S Latini; L Binderup
Journal:  Endocrine       Date:  1995-04       Impact factor: 3.633

4.  Skin-derived TSLP systemically expands regulatory T cells.

Authors:  Theresa M Leichner; Atsushi Satake; Victor Sanoe Harrison; Yukinori Tanaka; Angela S Archambault; Brian S Kim; Mark C Siracusa; Warren J Leonard; Ali Naji; Gregory F Wu; David Artis; Taku Kambayashi
Journal:  J Autoimmun       Date:  2017-01-23       Impact factor: 7.094

5.  Computer-aided de novo ligand design and docking/molecular dynamics study of vitamin D receptor agonists.

Authors:  Xiu-Long Shen; Midori Takimoto-Kamimura; Jing Wei; Qing-Zhi Gao
Journal:  J Mol Model       Date:  2011-04-27       Impact factor: 1.810

Review 6.  Vitamin D3 and skin diseases.

Authors:  K Kragballe
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

Review 7.  Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris.

Authors:  D Murdoch; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

8.  Vitamin D Suppresses Ovarian Cancer Growth and Invasion by Targeting Long Non-Coding RNA CCAT2.

Authors:  Liye Wang; Shuang Zhou; Bin Guo
Journal:  Int J Mol Sci       Date:  2020-03-27       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.